Claims
- 1. A method for the treatment of cancer, said method comprising administration of 4-desacetyl-4-methylcarbonate taxol and doxorubicin to a patient in need thereof.
- 2. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are administered sequentially.
- 3. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are administered simultaneously.
- 4. The method as claimed in claim 2, wherein said doxorubicin is administered initially followed by administration of 4-desacetyl-4-methylcarbonate taxol.
- 5. The method as claimed in claim 2, wherein said 4-desacetyl-4-methylcarbonate taxol is administered initially followed by administration of doxorubicin.
- 6. The method as claimed in claim 1, wherein said doxorubicin is administered in a dosage unit ranging between about 40-200 mg.
- 7. The method as claimed in claim 1, wherein said doxorubicin is administered in a dosage unit ranging between about 40-150 mg.
- 8. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol is administered in a dosage unit ranging from between about 50-380 mg.
- 9. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol is administered in a dosage unit ranging from between about 50-300 mg.
- 10. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are sequentially infused into a patient and the interval between infusions ranges between about 30 minutes to about 24 hours.
- 11. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are sequentially infused into a patient and the interval between infusions is about one hour.
- 12. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are administered via an administration means selected from the group consisting of intravenous administration, intramuscular administration, intraperitoneal injection and oral administration.
- 13. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are administered intravenously.
- 14. The method as claimed in claim 1, wherein said cancer is selected from the group consisting of breast cancer, ovarian cancer and lung cancer.
RELATED APPLICATION
[0001] This application claims the benefit under Title 35 § 119(e) of U.S. Provisional Application No. 60/234,496, filed Sep. 22, 2000. This application is a divisional of co-pending U.S. patent application Ser. No. 09/954,953 filed on Sep. 18, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60234496 |
Sep 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09954953 |
Sep 2001 |
US |
Child |
10728015 |
Dec 2003 |
US |